The Trump administration announced an expansion to TrumpRx, aiming to add more than 600 generic medications for sale.

The decision broadens the platform’s offering, which previously focused exclusively on discounted branded drugs from deals negotiated directly with manufacturers. The move is also expected to incorporate price comparison tools and partnerships with Cost Plus Drugs, Amazon Pharmacy, and GoodRx, positioning the site as a centralized hub for cash-paying patients seeking the lowest available prices at local pharmacies or through home delivery.

What are the details of the expansion?

President Trump announced the expansion at a public event on Monday, where executives from the platform's industry partners were also present. "By incorporating this massive catalog of low-cost generics at TrumpRx.gov, consumers will now have one source to ensure that they're getting the lowest possible cost on their prescription," Trump said.²

The updated platform lists commonly used generic medications including atorvastatin, clopidogrel, lisinopril, and metformin, drugs that are taken by tens of millions of Americans for cholesterol, blood clotting, hypertension, and diabetes, respectively.¹

Along with the drug offering expansion, patients will also have the ability to now compare cash prices across pharmacies in their area or opt for direct delivery, with discounts from Amazon Pharmacy, Cost Plus Drugs, and GoodRx integrated directly into the site.¹ The administration claims TrumpRx has been visited more than 10 million times since its February 2026 launch and has generated more than $400 million in savings for patients, though those figures have not been independently verified.

In a previous conversation with Pharmaceutical Executive, Lindsay Bealor Greenleaf, Head of market access policy strategy ADVI, noted how savings was the main focus of the program during its initial launch, saying, “It's meant to be a bigger, broader program focused on how to get patients access to the lowest cash pay price or greatest, coupon or discount that they can access.”

The generic drug listings are expected to be maintained separately from the branded medication discounts negotiated under Trump's Most-Favored-Nation pricing agreements, deals the administration says it has now struck with 17 major pharmaceutical manufacturers since September 2025.

According to the White House fact sheet, the platform will not include controlled substances, drugs subject to FDA-mandated risk evaluation and mitigation strategies, or medications not commonly sold through direct-to-consumer channels.¹

What is TrumpRx and why does it matter?

TrumpRx does not sell medications directly to patients, rather it functions as a price aggregator and referral platform, directing patients either to manufacturer-run direct-to-consumer sites offering discounts or providing coupons redeemable at retail pharmacies.

The platform targets patients willing to pay cash and bypass their insurance, a population that includes the uninsured, underinsured, and those whose co-pays exceed available cash prices.

What are the limitations?

Whether insured patients will meaningfully benefit from the expansion remains an open question. TrumpRx is explicitly designed for cash payers, and patients with comprehensive coverage may find their co-pays already competitive with or lower than the listed cash prices, thus the platform's value proposition is strongest for those currently paying out-of-pocket or navigating high-deductible plans.

Sources

1. Fact Sheet: President Donald J. Trump Announces Expansion of TrumpRx.gov to Bring Americans Transparency and Choice on Everyday Medicines The White House May 18, 2026 https://www.whitehouse.gov/fact-sheets/2026/05/fact-sheet-president-donald-j-trump-announces-expansion-of-trumprx-gov-to-bring-americans-transparency-and-choice-on-everyday-medicines/
2. US drugs site TrumpRx to list 600 generics as Trump targets lower prices Reuters May 18, 2026 https://www.reuters.com/business/healthcare-pharmaceuticals/trump-announce-discount-drug-pricing-expansion-white-house-official-says-2026-05-18/